Skip to main content

Megan N. Gates

Member / Chair, Corporate Practice; Co-chair, Securities & Capital Markets Practice

MNGates@mintz.com

+1.617.348.4443

Follow:
Share:

Megan guides public companies through structuring and implementing capital-raising transactions, SEC reporting compliance and corporate governance obligations, and strategic mergers and acquisitions. With a specific passion for the life sciences industry, Megan has over 25 years of experience in the biotechnology field. Her counseling is directly informed by a client-focused perspective she gained during a prior in-house counsel role with a global laboratory and analytical instrument maker.

Megan is Chair of the Corporate Practice, Co-chair of the Securities & Capital Markets Practice Group, and former member of the Firm's Policy Committee. She advises publicly traded and late-stage private companies, primarily in the life sciences industry, on capital raising, SEC reporting and corporate governance obligations, and merger and acquisition transactions.

As Chair of the Corporate Practice, Megan manages more than 140 attorneys in five offices across the US. Her responsibilities include managing the strategic direction of the group and implementing its key initiatives, marketing, hiring, personnel management, professional development, performance assessment, work allocation, budgeting, and financial analysis and management.

Megan frequently speaks at conferences on securities offerings, corporate governance, and compliance matters, including at Boston Bar Association panels and industry meetings. She is also active in community organizations in Boston, including serving as a Board member of the Pine Street Inn, the Boston Bar Foundation, and the Japan Society of Boston.

Before joining the firm in September 2000, Megan served as associate general counsel for Thermo Electron Corporation, where she was responsible for securities offerings and compliance for the corporation and its 23 publicly traded subsidiaries.

Megan guides public companies through structuring and implementing capital-raising transactions, SEC reporting compliance and corporate governance obligations, and strategic mergers and acquisitions. With a specific passion for the life sciences industry, Megan has over 25 years of experience in the biotechnology field. Her counseling is directly informed by a client-focused perspective she gained during a prior in-house counsel role with a global laboratory and analytical instrument maker.

Experience

Merger & Acquisition Transactions

  • Represented OvaScience in its merger with Millendo Therapeutics, Inc.
  • Represented Albireo Pharma, Inc. in its merger with Biodel Inc.
  • Represented ChyronHego Corporation in its $120 million acquisition by Vector Capital Partners
  • Represented Chyron Corporation in its acquisition of Hego Aktiebolag
  • Represented Caliper Life Sciences, Inc. in its $600 million acquisition by PerkinElmer Corporation
  • Represented Coley Pharmaceutical Group, Inc. in its $164 million acquisition by Pfizer Inc.
  • Represented Targacept, Inc. in its merger with Catalyst Biosciences, Inc.
  • Represented RegenMedTX, LLC in its acquisition by a private equity firm
  • Represented EPIRUS Biopharmaceuticals, Inc. in its acquisition of Bioceros Holding B.V.

Securities Offerings

  • Represented Bank of America – Merrill Lynch in a $138 million follow-on offering by Puma Biotechnology, Inc.
  • Represented OvaScience, Inc. in a $50 million follow-on offering
  • Represented OXiGENE, Inc. in multiple follow-on offerings
  • Represented MELA Sciences, Inc. in a $10 million follow-on offering
  • Represented NeuroMetrix, Inc. in multiple follow-on offerings
  • Represented Coley Pharmaceutical Group in its $102.6 million initial public offering
  • Represented Targacept, Inc. in its $40.7 million initial public offering
  • Represent H.C. Wainwright & Co., LLC in multiple follow-on offerings by biotechnology issuers
Read less

viewpoints

ERISA Fiduciaries May Consider ESG Factors in Selecting Investments and Exercising Shareholder Rights

November 30, 2022 | Alert | By Jacob Hupart, Michelle Capezza, Thomas R. Burton, III, Megan Gates

Read more

What Public Comments on the SEC’s Proposed Climate-Related Rules Reveal—and the Impact They May Have on the Proposed Rules

July 20, 2022 | Blog | By Jacob Hupart, Megan Gates, William F. Weld, Doug Baumstein, Jennifer Rubin, Courtney O. Taylor, Luke Haubenstock

This article provides a brief summary of the public comments submitted to the SEC regarding the Commission's proposed climate-related rules, and analyzes and summaries the key points the comments conveyed.
Read more

SEC Proposes Regulations to Address “Greenwashing” By Investment Funds

June 13, 2022 | Blog | By Jacob Hupart, Megan Gates, Doug Baumstein, Pete Michaels, Courtney O. Taylor, William F. Weld, Thomas R. Burton, III, Sahir Surmeli

In this article, Mintz attorneys explore the SEC's recently issued proposed regulations on "greenwashing" and how the rules would effect investment advisers and investment companies if implemented.
Read more
ESG Thumbnail

Who Should Be In Charge of Board ESG Responsibilities?

April 28, 2022 | Blog | By Jennifer Rubin, Jacob Hupart, Megan Gates

Read more
In this webinar, former Massachusetts Governor Bill Weld, and Members Megan Gates and Jacob Hupart, examine key takeaways from the SEC’s proposed climate-related disclosures rule.
Read more

A Brief Summary of the SEC’s Proposed Climate-Related Rules

March 30, 2022 | Advisory | By Jacob Hupart, Megan Gates, William F. Weld, Doug Baumstein, Jennifer Rubin, Courtney O. Taylor

Read more

SEC Proposes New Cybersecurity Rules for Public Companies

March 21, 2022 | Advisory | By Roman M. Gorokhov, Cynthia Larose, Megan Gates, John Condon

Read more

Preparation for 2021 Fiscal Year-End SEC Filings and 2022 Annual Shareholder Meetings

January 18, 2022 | Advisory | By Megan Gates, John Condon, Anne Bruno, Melanie Ruthrauff Levy, Daniel T. Kajunski, Cynthia Larose, Breton Leone-Quick, Page R. Hubben

Read about key regulatory and other developments, including board diversity and other ESG matters, which public companies need to consider as they prepare for their fiscal year-end SEC filings and 2022 annual shareholder meetings.
Read more
Join Tom Burton, Chair of the Mintz Energy & Sustainability Practice, Megan Gates, Chair of the Mintz Corporate Practice and Co-chair of the Mintz Securities & Capital Markets Practice, Dan Romito, Partner, Consulting – ESG Strategy & Integration at Pickering Energy Partners, and Sarah Borg-Olivier, Chief Operating Officer and Senior Vice President at Instar Asset Management for a discussion on the practical considerations surrounding ESG. 
Read more

Environmental Disclosures: Considerations for Board Members

September 17, 2021 | Blog | By Jacob Hupart, Megan Gates, Jonathan L. Kravetz, Doug Baumstein

Read more
Read less

News & Press

Press Release Thumbnail
35 Mintz attorneys have been named Massachusetts Super Lawyers and 25 Mintz attorneys have been named Massachusetts Rising Stars for 2022.
Press Release Thumbnail
The deal will take public ProKidney, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, and is expected to provide up to $825 million in gross cash proceeds.
News Thumbnail
Mintz Member, Chair of the firm’s Corporate Practice, and Co-chair of the Securities & Capital Markets Practice Megan Gates was quoted in an article published by Bloomberg Tax on auditors joining investors, regulators, rating agencies, and others in increasingly scrutinizing companies’ voluntary environmental, social, and corporate governance disclosures.
News Thumbnail
Mintz Member and Co-chair of the firm’s Securities & Capital Markets Practice Megan N. Gates was quoted in an article published by Law360 examining a sustained increase in at-the-market (ATM) offerings, a type of registered offering that allows public companies to sell shares in phases so they can seize attractive prices.
Press Release Thumbnail
In the latest guide, Mintz garnered rankings as a top national firm in eight practice areas, and 32 firm attorneys were individually recognized.
Megan Gates, Member and Co-Chair of Mintz’s Securities & Capital Markets practice, is quoted providing commentary in this Boston Business Journal feature article on how the partial government shutdown is impacting Massachusetts businesses. Megan specifically addresses how public stock offerings are being effected.
Mintz Member and Co-chair of the firm’s Securities & Capital Markets Practice Megan Gates is among the featured panelists at the 2017 Association of Corporate Counsel Annual Meeting.
Mintz represented G1 Therapeutics, Inc. in its initial public offering of 7,781,564 shares of common stock. G1 Therapeutics is a clinical-stage biopharmaceutical company.
Megan Gates, a Member and Co-chair of the Securities & Capital Markets Practice, is quoted in an Agenda article covering the SEC fining an audit firm for unprofessional conduct resulting from personal relationships.  
Daniel DeWolf, Co-Chair, Venture Capital and Emerging Companies, and Megan Gates, Co-chair of the Securities & Capital Markets Practice Group, authored this VC Experts Blog piece discussing how the world of raising capital has been evolving over the last several years.
Read less

Events & Speaking

Panelist
May
18
2022

28th Annual New England Energy Conference & Exposition

Demystifying Decarbonization

AC Hotel by Marriott l Worcester, MA

Conference Reference Image
Panelist
Mar
22
2022

Northeast Board of Directors Forum

Setting Expectations for 2022 Stakeholder Meetings

Virtual Event

Event Reference Image
Panelist
Panelist
Sep
15
2020
Webinar Reference Image
Moderator
Speaker
Apr
15
2020
Webinar Reference Image
Panelist
Jan
14
2020

Hot Topics for the Proxy Season

NACD New England

Offices of Deloitte, Boston

Webinar Reference Image
Speaker
Mar
27
2019

Women on Corporate Boards

Ellevate Network

Mintz, One Financial Center, Boston, MA

Webinar Reference Image
Moderator
Jan
14
2019

14th Annual Directors Forum

Global risk factors: preparing for the unpredictable

San Diego, CA

Speaker
Jun
12
2018

Director Education Forum 2018

American College of Corporate Directors

Dedham, MA

Speaker
May
22
2018

Basics for Directors,Understanding Board Mandatory Filings

American College of Corporate Directors

Webinar

Panelist
Jun
7
2017

2017 Public Markets Overview

Broadview Ventures, Inc.

Boston, MA

Speaker
Jun
15
2016

Director Education Forum 2016

American College of Corporate Directors

Dedham, MA

Speaker
Feb
11
2016

A Day in the Life of a Board Executive: Legal Responsibilities and Fiduciary Duties

Boston Women in Finance

Two Financial Center, Boston, MA

Speaker
Jun
10
2015

Director Education Forum 2015

American College of Corporate Directors Boston Forum

Speaker
Feb
11
2015

Public Company Director 101

Corporate Directors Group

Webinar

Read less

Megan guides public companies through structuring and implementing capital-raising transactions, SEC reporting compliance and corporate governance obligations, and strategic mergers and acquisitions. With a specific passion for the life sciences industry, Megan has over 25 years of experience in the biotechnology field. Her counseling is directly informed by a client-focused perspective she gained during a prior in-house counsel role with a global laboratory and analytical instrument maker.

Recognition & Awards

  • Chambers USA: Massachusetts: Capital Markets (2022)
  • Recommended by The Legal 500 United States for Healthcare: Life Sciences (2020 – 2022); Capital Markets: Equity (2021 – 2022)
  • Casa Myrna: Recipient of Norman Knight Charitable Foundation Award (2014)
  • Women’s Business Boston: Top 10 Corporate Lawyers (2010)
  • Massachusetts Lawyers Weekly: Top Women of Law (2010)
  • Phi Beta Kappa
  • Best Lawyers in America:  Corporate Law (2023)
  • Massachusetts Super Lawyers list: Securities & Corporate Finance (2022)
Read less

Megan guides public companies through structuring and implementing capital-raising transactions, SEC reporting compliance and corporate governance obligations, and strategic mergers and acquisitions. With a specific passion for the life sciences industry, Megan has over 25 years of experience in the biotechnology field. Her counseling is directly informed by a client-focused perspective she gained during a prior in-house counsel role with a global laboratory and analytical instrument maker.

Involvement

  • Member, Boston Bar Association Council
  • Corporate Board Committee, The Boston Club
  • Life Sciences Council, Springboard Enterprises
  • Board of Directors, Wellesley College Business Leadership Council
  • Board of Directors, Greater Boston Legal Services
  • Curriculum Committee, Massachusetts Continuing Legal Education (MCLE)
  • Board of Directors, Pine Street Inn, a nonprofit organization that is New England’s largest resource for homeless men and women
  • Co-chair, Boston Bar Foundation John & Abigail Adams Benefit (2016)
  • Past Chair, Board of Directors, Casa Myrna, a nonprofit organization located in Boston that is working to end domestic violence in the lives of women and children
  • Past Co-chair, Boston Bar Association Business Transactions Section and Securities Law Committee
Read less

Megan N. Gates

Member / Chair, Corporate Practice; Co-chair, Securities & Capital Markets Practice

Boston